A new model of care, built around people, for every stage of family building and women’s health

Pete Anevski is the Chief Executive Officer at Progyny, where he leads the company’s strategic vision and growth as it transforms the family building and women’s health benefits industry. With decades of experience building and scaling operations at leading healthcare and technology companies, Pete is driving Progyny’s aim to deliver equitable, high-quality care for women and families.

Under Pete’s leadership, Progyny has expanded its footprint to support millions of lives across the U.S. and globally, while introducing new solutions that address care gaps across fertility, maternal health, parenting, menopause, and midlife. He is a passionate advocate for redefining the standard of care, building an integrated, data-driven model that improves outcomes, enhances the member experience, and lowers costs for employers.

Prior to becoming CEO, Pete served as Progyny’s President and Chief Financial Officer. Before joining Progyny, he was Chief Financial Officer at WebMD, where he helped scale the organization and expand access to health information for millions of consumers.

A recognized industry leader, Pete was named to the TIME100 Health list for protecting access to IVF, Ernst & Young’s Entrepreneur of the Year, Crain’s New York Notable Leader in Healthcare, and a Champion for Women's Health by The World Economic Forum. A frequent speaker on the future of women’s health and family building benefits and continues to work closely with top employers, consultants, and policymakers to champion access and innovation.

Dr. Janet Choi is the Chief Medical Officer at Progyny, where she leads the company’s clinical strategy and ensures Progyny’s solutions deliver the highest quality care across the family building and women’s health continuum. A double board-certified reproductive endocrinologist and OB/GYN, Dr. Choi brings over three decades of clinical leadership and hands-on patient care experience to Progyny’s mission of expanding access, improving outcomes, and setting a new standard in reproductive healthcare.

Before joining Progyny, Dr. Choi served as Medical Director at CCRM New York and previously held academic and clinical leadership roles at Columbia University Medical Center, where she was Director of Onco-Fertility and Co-Director of the Fertility Preservation Program. She has authored numerous publications and lectures nationally on fertility preservation, onco-fertility, and reproductive aging.

Dr. Choi is a Menopause Society Certified Practitioner (MSCP), sits on the medical advisory board of The Chick Mission, and serves as a medical advisor to Respin Health. She is an active member of the American Society for Reproductive Medicine and the American College of Obstetricians and Gynecologists. She has been recognized as a Castle Connolly’s “Top Doctor”, one of New York Magazine’s Top Doctors, and a Castle Connolly Exceptional Woman in Medicine.

Dr. Choi earned her A.B. in English literature from Harvard University, graduating magna cum laude. She received her M.D. and completed her residency in Obstetrics and Gynecology at Columbia University, followed by a fellowship in Reproductive Endocrinology and Infertility at Weill Cornell Medical College.

Geoffrey Clapp is the Chief Product Officer at Progyny, leading the strategy and development roadmap for Progyny’s expanding portfolio of high-impact, scalable solutions designed to improve access to family building and women’s health care. With deep experience building innovative platforms that center on patients and providers, Geoffrey helps drive Progyny’s product evolution with the same level of clinical excellence, personalization, accessibility, and superior outcomes the company is known for.

Prior to joining Progyny, Geoffrey served as Senior Vice President and Head of Strategy at Optum Health Solutions, where he reimagined and rebuilt core products in renal care and organ transplant, driving significant earnings growth and improved outcomes. Earlier in his career, he co-founded a market-leading remote patient monitoring company—acquired by Bosch—and has led product and engineering teams at several healthcare startups and organizations globally. He is a recipient of Business Week’s Best Product award for his work in chronic disease management and is known for bridging clinical insight with cutting-edge technology.

Geoffrey holds a Bachelor of Arts from Goucher College in Computer Science and Cognitive Psychology.

Melissa Cummings is the Chief Operating Officer at Progyny, playing a critical role in scaling Progyny’s operations and building on capabilities and advancing the differentiated service and support Progyny offers today. Known as a dynamic change leader with a deep customer and provider focus, Melissa brings a broad skill set spanning P&L leadership, corporate strategy, product development, sales, technology, and operations. Her ability to lead with both vision and execution has consistently delivered measurable results and improved outcomes for organizations, clients, and the communities they serve.

Prior to joining Progyny, Melissa served as EVP and Chief Customer Officer at Blue Cross and Blue Shield of RI (BCBSRI) where she led record growth, retention and brand recognition for this $2 billion plan across both commercial and government segments. Melissa led the evolution of the firm’s retail strategy, along with a number of market-leading customer service capabilities – including the first of its kind navigation and advocacy solution – and directed sales, product, marketing, operations and enterprise strategic planning. Melissa has also held senior leadership positions at Aetna (now CVS Health) and CIGNA in business operations, product development and management, underwriting and sales.

Melissa holds a B.A. from the College of the Holy Cross and an M.B.A. in Health Care Management from the University of Connecticut. She is deeply involved with the American Heart Association, serving as Past Board Chair for the Southern New England Board of Directors, and a former Go Red chairperson. She currently serves on the Board for RI PBS/NPR and chairs the organization’s Development Committee.

Risa brings her results-oriented approach to lead all brand, marketing, and communications activities at Progyny. Risa has over 20 years of experience in the healthcare industry, with a focus on communications, investor relations, and business development. Prior to joining Progyny, she was Vice President of Investor Relations at WebMD.

With over 25 years of healthcare experience, Katie Higgins will be overseeing the teams that drive revenue, business growth, and client success. Prior to Progyny, Higgins was the Chief Revenue Officer at Crossover Health, a national medical group providing an innovative model of advanced primary care to the country's largest self-insured employers, where she spearheaded the company's go-to-market strategy. Prior to her tenure at Crossover, Katie spent three impactful years at Optum, where she led teams in crafting innovative collaborations with health systems, and 20 years at the Advisory Board Company, where she played a pivotal role in leading strategic account teams that served as thought partners to some of the nation's largest health systems. Katie holds a Bachelor of Arts in Political Science from Davidson College in North Carolina.

Steven brings over 28 years of experience as a technology leader and will be overseeing the engineering, information technology, and cyber security functions. Prior to Progyny, Steven served as Vice President, Customer Technology at American Airlines, where he managed a global team of over 1,300 professionals, responsible for technology solutions that benefit both American Airlines’ customers and the dedicated team members who support them. Steven’s background also includes leadership roles in managing American’s global infrastructure and operations footprint, revenue and planning technology, and helping modernize airport operations systems during his tenure. Steven holds a Bachelor of Science in Computer Engineering from Texas A&M University.

Mark is a seasoned finance executive with demonstrated success transitioning entrepreneurial businesses to high growth corporate entities. Prior to joining Progyny, Mark was the Integration Management Officer at Scripps Networks driving its merger with Discovery Communications. He also served as SVP Finance and CFO International at Scripps, and in senior finance roles at Emerson Reid, Emdeon and Hess.

Cass brings her expertise in leading human resources, talent acquisition, learning and development and employee experience at growth stage companies to Progyny. Prior to joining Progyny, Cass was Director of Talent at SignPost and TravelClick, a global provider of innovative, cloud-based and data-driven solutions for hotels.

David brings over 25 years of healthcare and executive management experience to the company. During his tenure as CEO, Progyny reached many key milestones, including achieving five consecutive years of industry leading clinical outcomes, becoming the first fertility and family building company to go public, being added to the prestigious S&P 400 index, and significantly growing its clients and covered lives. Prior to joining Progyny, David was the CEO of WebMD.

Julie brings over two decades of strategy and leadership in business development at notable healthcare start-ups and some of the world’s largest health insurance companies. She leads a diverse team focused on Progyny’s strategy and growth execution across key partnerships, industry groups, and employer sales. Julie is passionate about Progyny’s mission and pairs her experience with employers, benefit consultants, and health plans to ensure that everyone has access to a comprehensive and supported fertility and family building benefit. Julie has been with Progyny since 2017, prior to joining Progyny, Julie held various roles at Cigna, Bloom Health, and ConsumerMedical.

Allison brings to Progyny an extensive understanding of the healthcare industry with experience in steering mission-driven organizations through matters across regulatory law, privacy, compliance, commercial contracts, litigation management, and more to achieve overall business objectives and growth.  

Allison was previously the Deputy General Counsel at K Health Inc., a growth-stage company, and prior to that she was with Centene Corporation, the largest managed care organization in the country, where she held multiple senior positions, including Regional General Counsel and Privacy Officer.   

She received a bachelor’s degree in history, a master’s degree in health administration, and a Juris Doctor degree from the University of Maryland.  

Pete brings more than two decades of leadership and experience in building and scaling operations at prominent healthcare companies to his role as Progyny’s Chief Executive Officer. Pete is a champion of expanding access to fertility and family building benefits in order to give everyone the opportunity to achieve their dream of parenthood. He has been working with leading employers to provide a comprehensive and inclusive fertility and family building benefit that is fully managed, generates superior clinical outcomes, and delivers exceptional care to their employees. Prior to joining Progyny, Pete was the CFO at WebMD.

David brings over 25 years of healthcare and executive management experience to the company. During his tenure as CEO, Progyny reached many key milestones, including achieving five consecutive years of industry leading clinical outcomes, becoming the first fertility and family building company to go public, being added to the prestigious S&P 400 index, and significantly growing its clients and covered lives. Prior to joining Progyny, David was the CEO of WebMD.

Elizabeth Bierbower has served as a member of our board of directors since May 2025. From 2022 to 2023, Ms. Bierbower served as Chairman, Chief Executive Officer, and a director of Friday Health Plans, a health insurance company. Prior to that, Ms. Bierbower held various positions at Humana Inc., including Segment President from April 2018 to December 2019, President of the Employer Group Segment from May 2012 to September 2018, Chief Operating Officer of the Specialty Benefits division from October 2008 to June 2012, and Vice President of Product Innovation from May 2001 to September 2008. Before that, Ms. Bierbower was Vice President of Program Management at Highmark Blue Cross Blue Shield from 1997 to 2001 and Chief Operating Officer at Coventry Health Care, Pennsylvania from 1989 to 1996. Ms. Bierbower currently serves on the board of directors of Option Care Health, a public company, and privately held Blue Sprig, Paradigm Corp., and Point32Health. She previously served on the board of directors of Iora Health, the American Telemedicine Association, and Quest Analytics. Ms. Bierbower has a B.A. in Sociology from Carlow University and a master’s degree in public management from Carnegie Mellon University. We believe that Ms. Bierbower is qualified to serve on our board of directors because of her more than 30 years of proven executive-level experience managing operations and P&L in the healthcare industry.

• Independent Director
• Member of the Nominating and Corporate Governance Committee

Lloyd Dean has served as a member of our board of directors since August 2022. Mr. Dean has served as the Chief Executive Emeritus and the Founding Executive of CommonSpirit Health since August 2022, where he previously served as the Chief Executive Officer from February 2019 to July 2022. Prior to that, he worked at Dignity Health (f/k/a Catholic Healthcare West) from 2000 to 2019, where he most recently served as Chief Executive Officer and President. Mr. Dean worked at Advocate Health Care as Chief Operating Officer from 1997 to 2000 and as Executive Vice President from 1995 to 1997. He has also held executive positions at EHS Healthcare and Consumer Health Services. Mr. Dean has served on the board of directors of McDonald’s Corporation, a public company, since August 2015, and Surgery Partners, Inc., a public company, since February 2026. In addition, Mr. Dean currently serves on the board of directors of Guidehouse. Mr. Dean previously served on the board of directors of Wells Fargo & Company from 2005 to 2018 and Golden Arrow Merger Corp until January 2026. Mr. Dean holds a Bachelor of Science in Sociology and a Master’s in Education from Western Michigan University, an honorary Doctorate of Humane Letters from the University of San Francisco, and an honorary Doctor of Science degree from Morehouse School of Medicine, California State University, and California Polytechnic State University. CommonSpirit Health has also established the Lloyd H. Dean Institute for Humankindness and Health Justice. We believe that Mr. Dean is qualified to serve on our board of directors because of his extensive knowledge and experience in healthcare.

• Financial Expert
• Independent Director
• Chair of the Nominating and Corporate Governance Committee
• Member of the Audit Committee

Kevin Gordon has served as a member of our board of directors since October 2019. Mr. Gordon has also served on the board of directors of privately held Worldwide Clinical Trials, a global contract research organization, since December 2023 and as a Kohlberg Operating Advisor thereto since July 2024. He served as an advisor to 3i Group’s North American healthcare portfolio companies from January 2022 to July 2024, including as a director of privately held Sanisure LLC and Cirtec Medical Corp., and currently serves as a director of Q Holdco Limited. Mr. Gordon served on the board of directors of Veracyte, Inc., a genomic diagnostics company, from December 2016 to June 2022. From January 2018 to March 2019, he was the President and Chief Financial Officer of Liquidia Technologies Inc., a clinical biopharmaceutical company. Mr. Gordon served as Executive Vice President and Chief Operating Officer of Quintiles Transnational Holdings Inc., or Quintiles, a research, clinical trial, and pharmaceutical consulting company, from October 2015 until its merger with IMS Health Holdings, Inc. (forming IQVIA Holdings, Inc.) in October 2016. Prior to that, he was the Executive Vice President and Chief Financial Officer of Quintiles from July 2010 to December 2015. Mr. Gordon served as Executive Vice President and Chief Financial Officer of Teleflex Incorporated, a medical device company, from March 2007 to January 2010, and he held various senior corporate development positions there from 1997 to 2007. Prior to that, Mr. Gordon held various positions at Package Machinery Company and KPMG LLP. Mr. Gordon holds a B.S. in Accounting from the University of Connecticut. We believe that Mr. Gordon is qualified to serve on our board of directors because of his extensive accounting experience and leadership experience at healthcare companies.

• Financial Expert
• Independent Director
• Chair of the Audit Committee

Roger Holstein has served as a member of our board of directors since November 2020. He has been a Managing Director at Vestar Capital Partners, a private equity firm, since 2006, and he currently serves on the board of directors of privately held Nox Health. Mr. Holstein previously served on the board of directors of Quest Analytics from June 2017 until December 2025. From 1997 to 2005, Mr. Holstein served as Chief Executive Officer, President, and Director of WebMD Health Corp., or WebMD, and helped establish it as the leading source of healthcare information for consumers and professionals. From 1991 to 1996, Mr. Holstein was a member of the Office of the President at Medco, where he helped create the business of prescription benefit management. Prior to that, he held executive positions at MCI, Warner Amex Cable, and Grey Advertising. Mr. Holstein began his career in marketing with the Spirits of St. Louis basketball team in the American Basketball Association. Mr. Holstein holds a B.A. with distinction from Swarthmore College. We believe that Mr. Holstein is qualified to serve on our board of directors because of his extensive leadership and healthcare experience.

• Independent Director
• Chair of the Compensation Committee
• Member of the Nominating and Corporate Governance Committee

Debra Morris has served as a member of our board of directors since January 2025. Ms. Morris currently serves as Executive Advisor to AccessHope, LLC and previously served as its President from November 2024 through December 2025. She served as its Chief Operating Officer and Chief Financial Officer from May 2024 to November 2024. Prior to that, Ms. Morris was Executive Vice President, Chief Financial Officer of Apria, Inc. from March 2013 to October 2022. Ms. Morris served as Chief Financial Officer of Americas for Sitel Group from February 2010 to February 2013. She was a Partner of Tatum LLC from 2004 to 2011, in which capacity she provided chief financial officer services for various contracted companies, including LifeMasters Supported SelfCare. From 1999 to 2003, Ms. Morris was Chief Financial Officer of Caliber Holdings Corporation. Prior to that, she served in various roles at CBRE Group, Inc., including Executive Vice President, Global Chief Accounting Officer and Global Integration from 1981 to 1999. Ms. Morris currently serves on the board of directors of Rexford Industrial Realty, Inc. and biote Corp, both public companies. She previously served on the board of directors of Alternative Logistics Technologies Holdco LLC (Everdriven) from May 2020 to February 2024 and Tatum LLC from 2008 to 2011. Ms. Morris holds a B.S. in Business Administration from Colby Sawyer College in New London, New Hampshire. We believe that Ms. Morris is qualified to serve on our board of directors because of her extensive finance and accounting expertise and extensive leadership experience.

• Financial Expert
• Independent Director
• Member of the Audit Committee

Jeff Park has served as a member of our board of directors since October 2019. Mr. Park has served as a President of EVERSANA, which is a leading provider of global services to the life sciences industry, since August 2025. From November 2023 to August 2025, Mr. Park served as the President of Waltz Health, a digital health business that helps patients and payers save costs on prescription drugs, until Waltz Health was acquired by EVERSANA in August 2025. From April 2019 to April 2022, he served as the Chairman and Chief Executive Officer of WellDyneRx, an independent pharmacy benefits manager. Mr. Park has served as a member of the board of directors of P3 Health Partners, a public company, since December 2021. From January 2018 to May 2018, he was the Interim Chief Executive Officer of Diplomat Pharmacy, Inc., or Diplomat, a provider of specialty pharmacy services. In addition, from June 2017 to February 2019, Mr. Park served on the board of directors of Diplomat. Prior to that, from July 2015 to July 2016, he was the Chief Operating Officer of OptumRX, the entity resulting from the merger of Catamaran Corporation, or Catamaran, and OptumRX, UnitedHealthcare Group’s free-standing pharmacy care services business. Before the merger, from March 2014 to July 2015, Mr. Park was Catamaran’s Executive Vice President, Operations and previously served as Catamaran’s Chief Financial Officer, beginning in 2006. Mr. Park also served as a member of the board of directors of Ray Graham Assoc. Illinois Disability, a not-for-profit association, from January 2010 to June 2016. Mr. Park holds a B.S. in Accounting from Brock University. We believe that Mr. Park is qualified to serve on our board of directors because of his extensive leadership experience in the pharmaceutical industry.

• Independent Director
• Member of the Compensation Committee

Norman Payson, M.D. has served as a member of our board of directors since December 2016. Dr. Payson was a co-founder of Healthsource and its Chief Executive Officer from 1985 to 1997, Chief Executive Officer of Oxford Health Plans from 1998 to 2002, Chairman of Concentra from 2005 to 2008, and Chief Executive Officer of Apria Healthcare Group Inc. from 2008 to 2012. Since 1997, Dr. Payson has served as President and a director of NCP, Inc., his family office, through which he engages in consulting and personal investment activities. In addition, he served as a strategic advisor for Evolent Health, Inc. from March 2014 to December 2020 and previously served on its board of directors from December 2013 to June 2019. Dr. Payson is currently serving on the board of directors of various private and not-for-profit companies, including Access Clinical Partners (d/b/a GoHealth Urgent Care), HPM National Advisory Board at the Mailman School of Public Health at Columbia, and USC Schaeffer Center Advisory Board. Dr. Payson is also on the board of directors of Elia Philanthropies (formerly Kiva Foundation), a private charitable foundation organized by Dr. Payson and his wife in June 1998. Until June 2020, Dr. Payson served on the board of City of Hope, where he now serves as director emeritus. He continues to serve on the boards of AccessHope and Beckman Research Institute, which are subsidiaries of City of Hope. Until June 2019, Dr. Payson served as a director at the Geisel School of Medicine at Dartmouth, where he now serves as director emeritus. From October 2016 to November 2023, he was on the board of directors of Smile Brands. From June 2021 to July 2022, Dr. Payson was Chairman of Implantable Provider Group. From May 2017 to August 2019, he was a board member of Healthcare Outcomes Performance Company, a subsidiary of The Center for Orthopaedic and Research Excellence, Inc. In October 2024, Dr. Payson joined the board of Stephenson Global Pancreatic Cancer Research Institute, and, in December 2024, Dr. Payson joined the board of Handpicked Health (formerly EmsanaCare). Dr. Payson has a B.S. in Earth and Planetary Sciences from the Massachusetts Institute of Technology and received his M.D. from Dartmouth Medical School. Dr. Payson is a California licensed physician. We believe that Dr. Payson is qualified to serve on our board of directors because of his 40-year career as chief executive officer or chairman of multiple healthcare organizations, including publicly traded companies.

• Independent Director
• Member of the Compensation Committee

Cheryl Scott has served as a member of our board of directors since October 2019. Since July 2016, Ms. Scott has served as the Main Principal of the McClintock Scott Group. From June 2006 to July 2016, Ms. Scott served as Senior Advisor to the Bill & Melinda Gates Foundation. Previously, she served as President and Chief Executive Officer of the Seattle-based Group Health Cooperative for eight years. She currently serves on a variety of private company and not-for-profit boards. Ms. Scott was a member of the board of directors of Recreational Equipment, Incorporated (REI) from 2005 to 2017 and served as the board chairperson from 2015 to 2017. In addition, Ms. Scott served as a member of the board of directors of Evolent Health, Inc., a public company, from November 2015 to December 2025. Ms. Scott received her B.A. in Journalism and M.H.A. from the University of Washington and is currently a Clinical Professor of Health Services at the University of Washington. We believe that Ms. Scott is qualified to serve on our board of directors because of her extensive career and experience in healthcare, leadership, and corporate governance, including her tenure as the Chief Executive Officer of Group Health Cooperative.

• Independent Director
• Member of the Nominating and Corporate Governance Committee
• Member of the Compensation Committee